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ABSTRACT
Peribiliary glands (PBGs) are niches in the biliary tree and containing heterogeneous endoder-
mal stem/progenitors cells that can differentiate, in vitro and in vivo, toward pancreatic islets.
The aim of this study was to evaluate, in experimental and human diabetes, proliferation of
cells in PBGs and differentiation of the biliary tree stem/progenitor cells (BTSCs) toward insulin-
producing cells. Diabetes was generated in mice by intraperitoneal injection of a single dose of
200mg/kg (N5 12) or 120mg/kg (N5 12) of streptozotocin. Liver, pancreas, and extrahepatic
biliary trees were en bloc dissected and examined. Cells in PBGs proliferated in experimental
diabetes, and their proliferation was greatest in the PBGs of the hepatopancreatic ampulla, and
inversely correlated with the pancreatic islet area. In rodents, the cell proliferation in PBGs was
characterized by the expansion of Sox9-positive stem/progenitor cells that gave rise to insulin-
producing cells. Insulin-producing cells were located mostly in PBGs in the portion of the biliary
tree closest to the duodenum, and their appearance was associated with upregulation of MafA
and Gli1 gene expression. In patients with type 2 diabetes, PBGs at the level of the hepato-
pancreatic ampulla contained cells showing signs of proliferation and pancreatic fate commit-
ment. In vitro, high glucose concentrations induced the differentiation of human BTSCs cultures
toward pancreatic beta cell fates. The cells in PBGs respond to diabetes with proliferation and
differentiation towards insulin-producing cells indicating that PBG niches may rescue pancreatic
islet impairment in diabetes. These findings offer important implications for the pathophysiol-
ogy and complications of this disease. STEM CELLS 2016; 00:000—000
SIGNIFICANCE STATEMENT
Peribiliary glands within biliary tree represent the niche of biliary tree stem/progenitors cells
that are able to differentiate in pancreatic beta cells. Whether these cells play a role in insulin
production in diabetes is unknown. Here, we demonstrated that in experimental and human
diabetes, cells within peribiliary glands proliferate and commit toward insulin-producing cells.
Peribiliary gland niche may rescue the pancreatic islet impairment in diabetes with important
implications for the pathophysiology and complications of this disease.
INTRODUCTION
Peribiliary glands (PBGs) of human and murine
biliary trees are niches containing heterogene-
ous stem/progenitor cells (biliary tree stem/
progenitor cells, BTSCs) [1, 2]. BTSCs have
been isolated from human (h) biliary trees,
and their phenotype, self-renewal capability,
and potentiality to differentiate into mature
cells have been extensively characterized both
in vitro and in vivo [3]. The hBTSCs express a
broad panel of stem cell markers, have long-
term (in vitro) persistence and self-renewal,
and are able to lineage restrict to different
mature cell fates [4]. The hBTSCs residing in
PBGs are endowed with the capacity for pan-
creatic endocrine differentiation, and indeed
they express biomarkers indicative of either an
intermediate endocrine pancreas differentia-
tion stage (Pdx1/Ngn3) or a mature islet cell
stage, with some of the cells expressing insu-
lin, depending on their location within the bili-
ary tree [2, 5].
The embryological development of liver
and pancreas in mammals is associated with
the appearance of a common biliopancreatic
progenitor, which differentiates in distinct line-
ages driven by specific transcriptional factors
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[6, 7]. Recently, Banga et al. [8] demonstrated that Sox9-
positive cells in the biliary tree could be genetically reprog-
rammed to pancreatic cells with the appearance of ectopic
duct-like structures in which cells express a variety of endo-
crine pancreatic markers in association with the improvement
of a glycemic profile.
The aim of this study was to investigate whether PBGs and
their associated hBTSCs could be involved in the pathophysiol-
ogy of diabetes. In particular, in the streptozotocin (STZ)-
induced experimental diabetes in murine (m) hosts, we eval-
uated the activation and proliferation of cells within PBGs and
whether mBTSCs are capable of differentiating toward endo-
crine pancreatic islet fates. In humans, we evaluated the activa-
tion of the PBG compartment in the extrahepatic biliary tree
(EHBT) of patients with type 2 diabetes (T2D) and the in vitro
response of hBTSCs to high glucose concentrations.
MATERIALS AND METHODS
Murine Model
Six-week-old male C57BL/6J mice (N5 49) were purchased
from Charles River Laboratories (Wilmington, Massachusetts,
MA, http://www.criver.com/) and housed at 22 8C with 12:12
hour light/dark cycles. Animals were fasted overnight, and
blood glucose levels were measured in an automatic glucose
monitor (Accu-Check Compact Plus, Roche Diagnostics, Basel,
Switzerland, CH, http://www.roche-applied-science.com) from
the tail vein.
The following groups have been investigated:
 High-dose STZ group: Twelve mice were intraperitoneally
injected with a single dose of 200mg/kg of STZ (Sigma-
Aldrich, St. Louis, Missouri, MO, http://www.sigmaaldrich.
com) in 0.1M citrate buffer pH 4.5 [9]. Nine mice were
injected with the equivalent volume of citrate buffer as
negative controls. Blood glucose levels were monitored at
1, 7, and 14 days after STZ treatment. We found that 12/
12 (100%) of the mice were rendered diabetic (blood glu-
cose levels> 300mg/dl) and were included in the study
[10]. Diabetic and control mice were sacrificed after 14
days.
 Low-dose STZ group: Twenty mice were intraperitoneally
injected with a single dose of 120mg/kg of STZ. Eight mice
were injected with the equivalent volume of citrate buffer
as controls. Blood glucose levels were monitored at 1, 7,
30, 45, 60, 75, and 90 days after STZ treatment. We found
that 12/20 (60%) mice were rendered diabetic (blood glu-
cose levels> 300mg/dl) and were included in the study
[10]. Diabetic mice were sacrificed after 30 days (low-dose
STZ D30: n5 6) or after 90 days (low-dose STZ D90: n5 6)
[8]. Control mice were sacrificed at 30 (n5 4) and 90
(n5 4) days after citrate buffer (the STZ carrier) injection.
At the end of the treatments, mice were sacrificed by cervical
dislocation. Urine samples were obtained, drawn directly from
the urinary bladder. Glucose concentration in the urine was meas-
ured by the Keto Diabur Test (Roche Diagnostics, Milan, Italy,
https://www.accu-chek.it/it/prodotti/urinari/index.html?product=ke-
todiaburtest5000). The HbA1c concentration was measured by
mouse glycated hemoglobin A1c (GHbA1c) ELISA Kit (cat # CSB-
E08141M, DBA, Milan, Italy, http://www.arp1.com/Glycated-
hemoglobin-A1c-GHbA1c-Mouse-ELISA-p/csb-e08141m.htm).
The study was approved by our local ethical committee at
Sapienza University of Rome. All animal experiments were
approved by the institutional animal care and use committee
of Sapienza University of Rome. Guide for the Care and Use
of Laboratory Animals, Eighth edition (2011) was followed.
Human Samples
hEHBT (N5 10) were obtained from cadaveric adult donors. All
tissues derived from adult liver grafts from the surgical depart-
ment of Sapienza University of Rome, Italy. Informed consent was
obtained from next of kin for use of the tissues for research pur-
poses, the study protocols received Institutional Review Board
approval, and processing was compliant with Good Manufacturing
Practice. On the basis of anamnestic and serological data, samples
were divided into normal (N5 5) or T2D (N5 5).
Light Microscopy and Immunohistochemistry
The murine EHBT (mEHBT) was dissected en bloc [11] using a Sur-
gical Microscope Zeiss (Zeiss OP-MI6 SD; Carl Zeiss, Goettingen,
Germany, http://www.zeiss.com/microscopy/en_de/home.html)
equipped with a digital videocam (Panasonic GP-KS162, Milan,
Italy, http://www.panasonic.com/it/). The gallbladder was individ-
uated and dissected; then, the dissection proceeded along cystic
duct, common bile duct, and hepatopancreatic ampulla. Finally,
the portion of duodenum near the hepatopancreatic ampulla
was cut, and the entire mEHBTwas collected (Fig. 1A).
The mEHBTs were fixed en bloc in 10% buffered formalin
and embedded in paraffin (55 8C–57 8C); serial 3lm-sections
were obtained and stained with hematoxylin & eosin and Mas-
son’s trichrome. Three to five serial sections were examined
for each specimen. At least three transversal-sectioned ducts
were scanned by a digital scanner (Aperio Scanscope CS Sys-
tem, Aperio Technologies, Oxford, U.K., http://www.leicabiosys-
tems.com/digital-pathology/aperio-digital-pathology-slide-scan-
ners) and processed by ImageScope [12]. Transversal diameter
was calculated for each duct (Fig. 1B, upper). No significant
differences were present among all examined ducts. The mean
of diameters of examined ducts was not significantly different
among groups. Pancreatic tissue at the level of the spleen
hilum and liver samples were also collected and processed.
Human pancreas, duodenum, and part of the EHBT were
obtained en bloc from routine orthotopic liver transplantation
procedures. The duodenal wall was sectioned, and the major
papilla was individuated. The head of the pancreas was dis-
sected, and the main pancreatic duct, the common bile duct
(choledocus), and the hepatopancreatic common duct were
visualized. For each case, human samples were taken at the
level of the hepatopancreatic ampulla. Human samples were
fixed in 10% buffered formalin and embedded in paraffin
(55 8C–57 8C) and processed for routine histological stains.
The PBG area was calculated as the volume fraction occu-
pied by PBG/total duct area and expressed as a percentage
both in mice (Fig. 1A, lower) and in human samples [13]. The
pancreatic islet area was measured by an image analysis sys-
tem (IAS—Delta Sistemi, http://www.delta-sistemi.it, Rome,
Italy) as the volume fraction occupied by islet/pancreatic area
and expressed as a percentage.
For immunohistochemistry, sections were incubated over-
night at 4 8C with a primary antibody against proliferating cel-
lular nuclear antigen (PCNA: mouse monoclonal; code:
M0879; dilution: 1:50; Dako, Glostrup, Denmark, http://www.
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dako.com) and Neurogenin 3 (Ngn3: rabbit polyclonal; code:
AB5684; dilution: 1:100; Millipore, Milan, Italy, http://www.
millipore.com). Samples were rinsed twice with phosphate
buffered saline (PBS) for 5 minutes, incubated for 20 minutes
at room temperature (RT) with secondary biotinylated anti-
body, and then with Streptavidin-horseradish peroxidase (HRP)
(LSAB1 System-HRP, Dako, code K0690). Diaminobenzidine
(Dako) was used as substrate, and sections were counterstained
with hematoxylin [14].
For immunofluorescence, nonspecific protein binding was
blocked by 5% normal goat serum. Specimens were incubated
with primary antibodies against Sox9 (rabbit polyclonal; code:
AB5809; dilution: 1:50; Millipore, Billerica, MA) and Insulin (Dako,
guinea pig polyclonal; code: IS002 dilution: 1:50). Then, specimens
were incubated for 1 hour at RT with labeled isotype-specific sec-
ondary antibodies (Alexafluor, Invitrogen, Life Technologies, Pais-
ley, U.K., http://www.invitrogen.com) and counterstained with
4’,6-diamidino-2-phenylindole (DAPI) for visualization of cell nuclei.
For all immunoreactions, negative controls were also included.
Sections were examined by Leica Microsystems DM 4500 B
Microscope (Weltzlar, Germany) equipped with a Jenoptik Prog
Res C10 Plus Videocam (Jena, Germany). Immunohistochemis-
try/immunofluorescence observations were processed with an
IAS—Delta Sistem and were independently performed by two
researchers in double blind fashion [15]. For quantitative analy-
sis, slides were scanned by a digital scanner (Aperio CS2 for
bright field and Aperio FL for immunofluorescence, Aperio Tech-
nologies, Oxford, U.K.) and processed by ImageScope. An image
analysis algorithm was used to quantify the percentage of cells
with PCNA, Sox9, and Ngn3 nuclear expression within PBGs. The
number of positive cells has been calculated as the percentage
of cells with positive nuclei with respect to the total number of
cells within PBGs. Similarly, an image analysis algorithm has
been used to quantify the percentage of insulin-positive cells
within PBGs. The number of positive cells has been calculated as
the percentage of positive cells with respect to the total number
of cells within PBGs. Counts have been performed in all glandu-
lar acini in each examined ducts.
Reverse-Transcription Polymerase Chain Reaction
Analysis
Total RNA was extracted by the procedures of Chomczynski
and Sacchi [16]. RNA quality and quantity was evaluated with
the Experion Automated Electrophoresis System. RNA
Figure 1. Models of experimental induced diabetes. (A): Isolation and surgical removal of the mouse extrahepatic biliary tree (EHBT). (B):
Hematoxylin and eosin (H&E) stains. EHBT (line in upper image) has been assessed in transversal section of the duct. Peribiliary gland area
has been calculated as the percentage of area occupied by glandular acini (blue line) with respect to the duct total area (red line). Original
magnification:3 20. (C): Blood glucose levels in high-dose STZ-treated mice and low-dose STZ-treated mice. *, p< .01 versus low-dose STZ-
treated mice. (D): H&E staining of pancreas in control and STZ-treated mice. In STZ-treated mice there was a reduction of pancreatic islet
area (circles) in comparison with controls. Original magnification:3 10. Abbreviations: CTR, control; D, day; STZ, Streptozotocin.
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equipped with the RNA StSens Analysis Chip (Bio-Rad Labora-
tories, Hercules, CA, http://www.bio-rad.com) was done as
previously described [17]. RNA was extracted by TRIZOL rea-
gent (Life Technologies, Rockville, MD, http://www.lifetech.
com; Cat# 15596-026) according to the manufacturer’s
instructions. 1 mg of RNA was retrotranscribed using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Life Technologies, Paisley, U.K., http://www.appliedbiosystems.
com: cod. 4368814), and cDNA was amplified using SensiMix
SYBR kit (Bioline, London, U.K.: cod. QT605-05, http://www.
bioline.com/us/sensimix-sybr-hi-rox-kit.html) according to the
manufacturer’s instructions.
The primers used were: Gli1: fw ACAAGTGCACGTTTGAA
GGCTGTC, rev GCTGCAACCTTCTTGCTC; Insulin: fw TATAAA
GCTGGTGGGCATCC, rev GCCATGTTGAAACAATGAC; Mafa: fw
TTCTCCTTGTACAGGTCCCG, rev GAGAGCGAGAAGTGCCAACT;
Ngn3: fw CTTCGTCTTCCGAGGCTCT rev CTATTCTTTTGCGCCGGTA
G; 18s: fwGCAATTATTCCCCATGAACG, rev GGGACTTAATCAA
CGCAAGC.
The expression of the gene of interest was calculated by
the ratio of the concentrations of the gene of interest and
the reference gene 18s.
Protein Extraction from Paraffin Embedded Samples
and ELISA for Insulin
Total proteins were extracted from formalin fixed paraffin embed-
ded (FFPE) sample block using the Qproteome FFPE Tissue Kit
(Qiagen, catalog # 37623, Qiagen Srl, Milan, Italy, http://www1.
qiagen.com). Briefly, three serial, 15lm thick sections were
obtained from the same FFPE block for each sample. Sections
were immediately placed in a 1.5ml collection tube; then, depar-
affinization and protein extraction was performed as indicated by
the vendor. The tissue content of mouse insulin was measured by
Mouse Ultrasensitive Insulin ELISA (ALPCO, catalog # 80-INSMSU-
E01, E10; Salem, US, http://w.alpco.com/products/Insulin_Ultra-
sensitive_Mouse_ELISA.aspx), normalized to the volume of the
origin tissue sample, and expressed as ng/ml per mm3 of tissue.
Human BTSC Isolation and In Vitro Studies
hBTSCs were obtained from organ donors from the ‘‘Paride
Stefanini’’ Department of General Surgery and Organ Trans-
plantation, Sapienza University of Rome, Rome, Italy. Informed
consent was obtained. Tissue specimens were processed as
described previously [3]. Cells were sorted for EpCAM (Milte-
nyi Biotec S.r.l., Bologna, Italy, http://www.miltenyibiotec.com)
by using magnetic beads [5]. Isolated hBTSCs were seeded
onto culture plastic at a density of 93 104 cells per cm2 or
2.53 104 cells per cm2 and cultured in serum-free Kubota’s
Medium (KM), a medium permissive for self-replication of
endodermal stem cells. Two culture conditions were tested:
 Basal (glucose concentration: 11mM): KM (pH 7.4) was
used.
 High glucose concentrations (glucose concentration: 22mM):
(1)-D-glucose (Sigma-Aldrich, St. Louis, Missouri, MO) was
added in KM to a final concentration of 22mM (pH 7.4).
Total RNA was extracted at 7 days and 14 days, and
reverse transcription polymerase chain reaction (RT-PCR) anal-
ysis was performed. Immunofluorescence analysis was per-
formed at 14 days.
Measurement of C-Peptide Secretion in hBTSCs
The hBTSCs were plated at 100,000 cells per well in 12-well
plates (3.85 cm2 surface area per well) and cultured in KM at
basal (11mM) or high glucose (22mM) concentration for 14
days. Medium was replaced every day. After 14 days, the
medium was removed, and the cultures washed twice with
PBS without calcium and magnesium. Medium was added to
the cells, incubated for 24 hours from each well of a 12-well
plate seeded with 100,000 cells per well, and then was col-
lected and stored at 220 8C. After media collection, the cells
were collected separately from each well and counted using
the Trypan blue exclusion assay. The human C-peptide concen-
tration in the medium of each well was measured by an ELISA
kit (Mercodia cod. N. 10-1136-01; Uppsala, Sweden, https://
www.mercodia.com/index.php?page=productview2&prodId=13),
normalized to the cell number of each sample, and expressed
as levels per 100,000 cells. Normal pancreatic islet cells were
purchased by ProdoLab, Irvine CA (HIR-001, http://prodolabs.
com) and used as positive controls. HepG2 cells were pur-
chased commercially from ATCC (No. HB-8065, Georgetown
University in Washington, DC, US; http://www.atcc.org/prod-
ucts/all/HB-8065.aspx) and were used as a negative control.
Statistical Methods
Continuous normally distributed variables are summarized and
presented as mean6 SEM. To compare the means between
groups for normally distributed data, analysis of variance or
the Student’s t test was performed. To determine differences
between groups having not normally distributed data, medians
were tested by Mann–Whitney U tests. The Pearson correlation
coefficient was used to determine correlations between contin-
uous normally distributed variables. The degree of association
between nonparametric or ordinal variables was assessed using
the Spearman nonparametric correlation. Statistical signifi-
cance was set to a p value< .05. Statistical analysis was per-
formed by SPSS statistical software (SPSS, Chicago, IL)
RESULTS
STZ-Induced Experimental Diabetes: Biochemical
Parameters
STZ resulted in an increase of glycemia (Fig. 1; Supporting
Information Tables 1, 2), glucose urinary levels (not shown),
and HbA1c (not shown) in comparison with controls.
In the high-dose STZ group, 12/12 mice showed a rapid
and marked increase of glycemia at 7 days, and this was sus-
tained until beyond 14 days, when the mice were sacrificed
(Fig. 1C; Supporting Information Table 1). High-dose STZ-
treated mice showed high urinary glucose levels at death, and
HbA1c was significantly increased (not shown).
In the low-dose STZ group, mice showed a less rapid
increase of glycemia in comparison with mice treated with
high dose of STZ. At D7, low-dose STZ group presented lower
glycemic levels in comparison with high-dose STZ group
(p< .05; Fig. 1C). Consistently, only 12/20 mice treated with
lower doses of STZ became diabetic. As shown in Figure 1C
and Supporting Information Table 2, in the low-dose STZ
group, glycemia reached the highest levels at D30 and then
stabilized.
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In STZ-treated mice, glucose serum levels correlated with
glucose urinary levels (r5.942, p< .001) and HbA1c (r5.817,
p< .001) while no differences were found among the three
(mice sacrificed at 14, 30, or 60 days after citrate buffer injec-
tion) control groups.
Pancreatic Islet Area and PBG Area in Normal
and STZ Mice
Treatment with STZ resulted in a reduction of pancreatic islet
area (Table 1). These values were significantly decreased com-
pared with that in normal pancreas (p< .05 vs. STZ groups)
(Fig. 1D). Insulin expression in pancreatic tissue in STZ-treated
mice was reduced in comparison with controls (not shown).
Interestingly, the level of pancreatic islet area was inversely
correlated with glycemia (r52.691, p< .001), HbA1c
(r52.558, p< .01), and glucose urinary levels (r52.652,
p< .02). No difference between the three control groups in
term of pancreatic islet area was observed (not shown).
We next evaluated the extension of the PBG area within
EHBTs (Fig. 2). No differences in PBG area were found among
the three control groups (not shown), and this was consistent
with similar glycemic profiles and pancreatic islet area.
Accordingly, all control mice were analyzed as a single group
(n5 17). The PBG area (Table 1) was significantly expanded in
the high-dose STZ group and in the low-dose STZ group in
Table 1. Morphometric and immunohistochemical analysis
Control High-dose STZ D14 Low-dose STZ D30 Low-dose STZ D90
Pancreatic islet area (lm2) 1.936 0.94 0.556 0.52* 0.216 0.11* 0.316 0.27*
Bile duct diameter (lm) 1176 18.4 123.36 13.7 119.96 22.8 124.26 31.2
PBG area (lm2) 5.056 1.98 7.176 1.72* 8.736 2.09* 11.636 3.64**
PAS-positive PBG cells (%) 3.36 1.5 18.36 3.5* 44.56 4.0*,*** 39.06 4.6*
PCNA-positive PBG cells (%) 7.26 1.9 35.86 4.7* 37.46 3.4* 23.66 5.4**
Sox9-positive PBG cells (%) 16.26 4.6 59.06 4.5* 57.46 7.7* 36.86 7.5**
Ngn3-positive PBG cells (%) 17.16 1.3 53.16 5.6* 48.06 8.7* 25.26 4.9**
Insulin-positive PBG cells (%) Negative 6.06 3.1* 7.06 3.1* 41.66 15.7**
D, day; PAS, Periodic Acid Schiff; PBG, peribiliary gland; STZ, streptozotocin.
*, p< .05 versus control group.
**, p< .05 versus other groups.
***, p< .05 versus high-dose STZ D14 group.
Figure 2. Peribiliary glands (PBGs) in induced experimental diabetes. (A): Hematoxylin and eosin (H&E) staining of extrahepatic biliary
tree (EHBT) in control and STZ-treated samples. At the level of the EHBT, STZ-treated mice showed a significant expansion of the PBG
area after high-dose STZ treatment and after 30 days (D30) and 90 days (D90) of low-dose STZ treatment in comparison with controls.
Original magnification:3 20. (B): H&E staining of hepatopancreatic ampulla in control and STZ-treated samples. At the level of the hepa-
topancreatic ampulla, STZ-treated mice showed a significant expansion of PBG area after high-dose STZ treatment, and after 30 and 90
days of low-dose STZ treatment in comparison with controls. Original magnification:3 20. (C): PAS staining of EHBT in control and STZ-
treated samples. STZ treatment resulted in an increase of PAS-positive cells within PBGs. Original magnification:3 20. Abbreviations:
CTR, control; PAS, Periodic Acid Schiff; STZ, Streptozotocin.
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comparison with control mice (p< .02). In the low-dose STZ
group, the PBG area was significantly higher at D90 compared
to mice sacrificed at D30 (p< .05) or to high-dose STZ treated
mice (p< .05). All examined ducts were comparable in size
(Table 1). Interestingly, the PBG area was inversely correlated
with those of pancreatic islets (r52.664, p< .05). The
increase of PBGs was also evident at the level of hepato-
pancreatic ampulla where the highest levels of PBG area were
evident (23.356 4.58 in the low-dose STZ D90 versus
10.876 2.83 in controls; p< .01; Fig. 2B).
We next analyzed the phenotypic traits of cells in PBGs.
STZ treatment dictated an increase of Periodic Acid Schiff-
positive cells within PBGs when compared to controls (Fig.
2C). In accordance with PBG expansion, the number of prolif-
erating (PCNA-positive) cells within PBGs was increased after
STZ treatment when compared to controls (Fig. 3A).
The increase of PBG area in STZ-treated mice was charac-
terized by the expansion of Sox9-positive stem/progenitor-like
cells (Fig. 3B; Table 1). In normal PBGs, Sox9-positive cells rep-
resented a small population, restricted to deeper PBG acini.
In high-dose D14 and low-dose D30 STZ-treated mice, Sox9-
positive cells sprouted toward the surface and represented
most of the PBG cells and surface epithelial cells (p< .05).
When low-dose STZ mice were examined after 90 days of
treatment, a lower percentage of Sox9-positive cells was pres-
ent in comparison with other STZ treated groups (p< .05).
STZ-treated mice were also characterized by the expansion
of Ngn3-positive stem/progenitor-like cells (Fig. 3C; Table 1)
within PBGs. In high-dose D14 and low-dose D30 STZ-treated
mice, Ngn3-positive cells sprouted toward the surface and
represented most of the PBG cells and surface epithelial cells
(p< .05 versus normal mice). Interestingly, when low-dose
STZ mice were examined after 90 days of treatment, a lower
percentage of Ngn3-positive cells was present in comparison
with other STZ treated groups (p< .05).
PBG Cells Expressed Insulin After STZ Treatment
In normal mice, insulin was expressed in beta cells within
pancreatic islets; whereas, acinar cells, pancreatic ducts, EHBT
and associated PBGs were essentially insulin-negative (Fig. 4A;
Table 1). In the high-dose STZ group, few cells within PBGs
were insulin-positive. Similarly, in the low-dose STZ group, at
D30, few cells within PBGs showed positivity for insulin. Inter-
estingly, this percentage massively and significantly increased
in mice sacrificed after 90 days (p< .05 vs. low-dose STZ,
D30, and high-dose STZ, D14, groups); in the low-dose STZ
group at D90, also surface epithelial cells were diffusely posi-
tive for insulin (Fig. 4A).
We next investigated in the low-dose STZ D90 group, the
distribution of insulin-expressing cells along the EHBT. Inter-
estingly, a gradient of insulin expression was evident with a
lower number of positive cells in PBGs of the cystic duct and
Figure 3. Activation of progenitor cell compartment in peribiliary glands (PBGs). (A): Immunohistochemistry for PCNA. The number of
PCNA-positive cells in PBGs increased after STZ treatment when compared to controls. Original magnification:3 40. (B): Immunofluores-
cence for Sox9 (red) in extrahepatic biliary tree (EHBT) in control and STZ-treated mice. The percentage of Sox9-positive cells increased
in STZ-treated mice in comparison with control (CTR) mice. Original magnification:3 20. (C): Immunohistochemistry for Ngn3 in EHBT in
control and (STZ)-treated mice. The percentage of Ngn3-positive cells increased in STZ-treated in comparison with control (CTR) mice.
Original magnification:3 40. Abbreviations: CTR, control; NGN3, Neurogenin 3; PCNA, proliferating cell nuclear antigen; STZ,
streptozotocin.
6 Peribiliary Glands in Diabetes
VC AlphaMed Press 2016 STEM CELLS
hilar hepatic duct and a higher number in the distal choledo-
cus and hepatopancreatic ampulla. In particular, at the level
of the hepatopancreatic ampulla, insulin was diffusely
expressed in PBG cells and surface epithelium, and islet-like
structures could occasionally be found at the bottom of glan-
dular elements (Fig. 4B). In the low-dose STZ D90, but not in
the other groups, insulin expression within PBG cells was
inversely correlated with glycemic levels (r52.66; p< .05).
Immunohistochemical data on biliary tree samples were
confirmed by RT-PCR. RT-PCR was performed in specimens
taken at the level of the liver hilum. These specimens were
divided into two parts that were separately processed for RT-
PCR and histology. Histological examination ruled out the
presence of pancreatic tissue within liver specimens. Immuno-
histochemistry demonstrated that hepatocytes and interlobu-
lar bile ducts were constantly negative for insulin in all groups
(not shown). By RT-PCR, EHBT tissues showed a significant
increase in insulin, MafA and Gli1 gene expression in the low-
dose STZ D90 versus controls (Fig. 3D; p< .05). In contrast,
Insulin, MafA, and Gli1 gene expression levels were similar
between low-dose STZ D30, high-dose STZ D14, and controls
(data not shown).
Finally, to confirm insulin production at protein levels,
ELISA tests for insulin were performed on tissue extracts (Fig.
4D). Insulin content increased in EHBT tissue in the low-dose
STZ D90 group in comparison with normal (p< .05); insulin
content in EHBT tissue from the low-dose STZ D90 group was
decreased with respect to the normal pancreatic tissue
(p< .01).
Proliferation of Human PBG Cells and Insulin
Expression Were Increased in Hepatopancreatic Ducts
from T2D Patients
In adult human T2D samples, the PBG area (Fig. 5A) at the
level of hepatopancreatic ampulla was significantly expanded
(30,350lm26 1,922; 7.58%6 0.68) in comparison with nor-
mal subjects (23,890lm26 1,806; 5.68%6 0.55; p< .01). In
keeping with PBG expansion, the number of proliferating
(PCNA-positive, Fig. 5A) cells within PBGs was increased in
T2D (55%6 5) when compared to normals (36.7%6 5.6,
p< .01; Fig. 5A). Consistently, in the T2D samples (at the
Figure 4. Differentiation of stem/progenitor cells of peribiliary glands (PBG) toward insulin-producing cells. (A): Immunofluorescence for
Insulin (green) in pancreas and EHBT in control and STZ-treated samples. In STZ-treated mice, peribiliary gland (PBG) cells were positive for
insulin; positive cells mostly increased in number after 90 days (D90) of low-dose STZ treatment. Original magnification:3 20. (B): In the
hepatopancreatic ampulla after 90 days of low-dose STZ treatment, insulin was diffusely expressed in PBG cells and in the surface epithe-
lium; islet-like structures could be found occasionally at the bottom of glandular elements (magnified at3 40). Original magnification:3 20.
(C): EHBT tissue showed a significant increase in Insulin, MafA, and Gli1 gene expression in low-dose STZ after 90 days of treatment in
comparison with controls.*, p< .05 versus CTR. (D): ELISA tests for insulin: EHBT tissue samples showed a significant increase in insulin
content in low-dose STZ after 90 days of treatment in comparison with normal EHBT samples.*, p< .05 versus other groups. Abbreviation:
STZ, streptozotocin.
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hepatopancreatic ampulla), a higher percentage of cells within
PBGs were insulin positive (13.67%6 5.13) in comparison
with normals (6%6 1; p< .05).
In Vitro Effects of High Glucose Concentrations
on hBTSCs
BTSCs were isolated from human EHBT. The (1)-D-glucose
concentration was doubled in the media of human BTSCs and,
after 7 and 14 days, RT-PCR analyses were carried out. As
shown in Figure 5B, after 14 days, the gene expression for
Ngn3, MafA, and Insulin was markedly increased (p< .01;
n5 5). By immunofluorescence, in basal conditions almost all
cells were positive for stem cell markers (EpCAM and Sox9)
and negative for insulin (not shown); after 14 days in high
glucose concentration, the appearance of islet-like structures
composed of densely packed insulin-positive cells was
observed (Fig. 5C). In addition, ELISA tests for C-peptide fur-
ther confirmed insulin production at the protein level, and its
secretion in the culture medium after incubation in high glu-
cose concentration in comparison with basal conditions
(p< .05 vs. basal conditions; Fig. 5D).
DISCUSSION
The PBGs in mice and in humans have been shown to contain
stem/progenitors that respond to regenerative demands
imposed by diabetes. The main findings of our study (Fig. 6)
indicate that: (a) cells within PBGs proliferated in an experi-
mental model of type 1 diabetes. The proliferation was greatest
at the hepatopancreatic ampulla following decreased pancreatic
islet area; (b) proliferation of cells within PBGs was associated
with the expansion of the Sox9-positive stem/progenitor cell
compartment. In bile ducts of normal mice, the BTSC compart-
ment resided at the bottom of PBGs, while in diabetic mice it
expanded occupying most of the glandular elements and the
surface epithelium; (c) Sox9-positive BTSCs within PBGs became
insulin-producing cells in diabetic mice in which they were
Figure 5. Human BTSC in type 2 diabetic patients and their in vitro response to high glucose. (A): Immunohistochemistry for PCNA (upper)
and immunofluorescence for insulin (lower). Peribiliary gland (PBG) area and the number of PCNA (proliferating cells) and insulin positive
cells within PBGs were increased in biliary tree specimens obtained from type 2 diabetic patients in comparison with normal controls. Origi-
nal magnification (OM):3 20 (upper) and 310 (lower). Area in the boxes is magnified in the inserts. (B–D): Human BTSCs isolated from nor-
mal biliary trees were cultured in basal (low glucose concentration: 11mM) conditions or exposed to high glucose concentration (22mM).
(B): After 14 days in high glucose concentration, the expression of Ngn3, MafA, and Insulin genes was significantly increased. *, p< .01. (C):
Immunofluorescence for EpCAM, Sox9, and insulin. In basal conditions, cultures were mostly composed of EpCAM-positive and Sox9-positive
cells. After 14 days in high glucose concentration, insulin-positive cells appeared. Original magnification:3 20. KM: Kubota’s medium, a
serum-free medium designed for endodermal stem/progenitors. (D): ELISA test for C-peptide further confirmed the increasing of insulin pro-
duction by human BTSCs at protein level and its secretion in the culture medium after incubation in high glucose concentration in compari-
son with basal conditions (*, p< .05 vs. others). Pancreatic islet and HepG2 cells were used as positive and negative controls, respectively.
Abbreviations: BTSC, biliary tree stem/progenitor cell; Ngn3, Neurogenin 3; PCNA, proliferating cell nuclear antigen.
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located mostly in the EHBT portion closest to the duodenum
and displayed upregulation of MafA and Gli1 gene expression.
(d) In humans, PBG hyperplasia, proliferation, and signs of
endocrine pancreatic commitment are observable in hepato-
pancreatic ampulla specimens from T2D patients. (e) With in
vitro studies, hBTSCs responded to high glucose concentration
with the upregulation of genes related to pancreatic islet cell
commitment and the synthesis and secretion of c-peptide.
The human biliary tree has been shown to be a reservoir
of stem and progenitor cells [1, 3–5, 18–20]. hBTSCs have
been shown able to self-replicate under defined, serum-free
conditions and then to be able to differentiate into either
hepatocytes, cholangiocytes, or pancreatic islets dictated by
the specifics of the differentiation conditions used [21]. When
transplanted into immunocompromised mice, hBTSCs were
able to repopulate cirrhotic liver and to correct experimentally
induced diabetes depending on where the cells were trans-
planted [1, 3–5, 18–20].
Here, we investigated the behavior of the BTSC niche in
experimental and human diabetes. In mice, diabetes was estab-
lished at two different STZ dosages. The high-dose STZ model
is characterized by a rapid increase of glycemic levels and high
mortality [9], allowing only a short time for observation. The
low-dose STZ model showed a slower increase of glycemia and
longer survival, allowing a prolonged observation time [8, 10].
In both models, hyperglycemia was correlated with HbA1c, glu-
cose urinary levels, and with pancreatic islet loss.
In STZ mice, a proliferation of cells within PBGs was evi-
dent. In the high-dose STZ model, PBG area rapidly increased
within 14 days; in the low-dose STZ model, PBG area increased
significantly after 30 days, and cells within PBGs continued to
proliferate during the succeeding 2 months. PBG cell prolifera-
tion was inversely correlated with the pancreatic islet loss. PBG
cell hyperplasia was associated with the expansion and prolifer-
ation of Sox9/Ngn3-positive cells. Previously, Dipaola et al. indi-
cated that proliferation of PBG cells occurs in experimental
models of cholestasis [11]. Beside their role in the turnover of
biliary epithelium, evidence has indicated that the biliary tree
constitutes the stem cell reservoir also for endocrine pancreas
[4]. In the developing pancreas, lineage-tracing experiments
Figure 6. Summary of key findings. (A): PBG compartments are located throughout the extrahepatic biliary tree but not in the gallblad-
der. PBGs are more numerous at the level of the hepatopancreatic ampulla. They are composed of cholangiocytes, goblet cells, and
Sox91 BTSC. (B): In our experimental models, the administration of high and low doses of STZ determined the reduction of pancreatic
islets and a correlated increase of PBG mass. PBGs are characterized by the expansion of proliferating Sox91/Ngn31 BTSCs, an increase
in mucin production, and the appearance of insulin-producing cells within PBGs at 14 (D14) and 30 (D30) days after high- and low-dose
STZ treatment, respectively. (C): At 90 days (D90) after the administration of low-dose STZ, the number of insulin-producing cells within
PBGs is highly increased; the greatest increase of PBG mass and insulin-producing cells occurs in the hepatopancreatic ampulla; (D) in
humans, PBG hyperplasia, proliferation, and signs of endocrine pancreatic commitment are observable in hepatopancreatic ampulla
specimens from type 2 (T2) diabetic patients in comparison with normal subjects. (E): Legend of the cell type. Abbreviations: Ngn3, neu-
rogenin 3; PBGs, peribiliary glands; PCNA, proliferating cell nuclear antigen; STZ, streptozotocin.
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demonstrated that all types of pancreatic epithelial cells have a
common origin from Sox9-expressing progenitors [22, 23]. On
the other hand, the role of Sox9-positive progenitor cells in
maintaining the homeostasis of the adult pancreas has
remained an important controversial issue [22, 24, 25].
Our recent findings indicated that BTSCs are precursors of
committed progenitors within the pancreas [4]. In these stud-
ies, we showed that in vitro under the same conditions of
serum-free KM, the hBTSCs were able to self-replicate indefi-
nitely, whereas human fetal pancreatic cells were able initially
to divide and undergo clonogenic expansion but after approxi-
mately eight divisions, the colonies transitioned into floating
aggregates that underwent differentiation toward islet cells.
The BTSCs remained as self-replicating cells but with the addi-
tion of various factors could be triggered at any time to go
through a similar process to that of the pancreatic cells to
form functional neoislets. Therefore, the pancreatic cells proved
to be committed pancreatic progenitors, and the BTSCs could
be lineage restricted to such progenitors by particular factors.
Transplantation of these neoislets in vivo into diabetic mice
resulted in an alleviation of hyperglycemia within 2 months [4].
In this study, we demonstrated that mouse PBGs activate
as a consequence of pancreatic islet loss induced by STZ.
Interestingly, previous reports indicated that pancreatic Sox9-
positive ductal cells, ones present in pancreatic ductal glands,
the known reservoirs of committed pancreatic progenitors, do
not differentiate into endocrine cells in a STZ-induced diabe-
tes model [26, 27]. In contrast, cells within PBGs rapidly and
constantly proliferated, and the related Sox9/Ngn3-positive
cell compartment was markedly expanded in our models.
Moreover, STZ treatment was able to determine not only a
proliferation but also a spatial reorganization of the PBG
niches. In normal conditions, Sox9/Ngn3-positive cells were
restricted to deeper PBG acini. After STZ treatments, Sox9/
Ngn3-positive cells extended toward the surface epithelium.
Moreover, PBG cells at the hepatopancreatic ampulla
showed the most prominent activation in terms of prolifera-
tion and insulin expression in comparison with those located
at the hepatic hilum or cystic duct. A proximal-to-distal axis in
the maturational lineages was described, going from stem
cells in PBGs nearest to the duodenum to committed progeni-
tors within the pancreatic duct glands in the pancreatic ducts
[2, 11]. In addition, our data further support previous sugges-
tions that PBGs at the level of the hepatopancreatic ampulla
contain a reservoir of endodermal stem cells that include pan-
creatic stem cells and their descendants, pancreatic commit-
ted progenitors [4].
In parallel with Sox9 and Ngn3 expression, mouse PBG
cells started to express insulin, thus indicating commitment
toward a pancreatic endocrine lineage. RT-PCR showed a mas-
sive upregulation of insulin gene expression associated with
the upregulation of MafA and Gli1 genes. MafA is a key tran-
scription factor for the terminal differentiation toward beta
cells [28]. Gli-1 is crucial for pancreas development and in
sustaining stem cell responses to regenerative needs [29].
To further translate our findings in humans, we evaluated
the PBG compartment in T2D patients and the in vitro
response of human BTSCs to high glucose concentration. In
keeping with results obtained from the experimental models,
PBGs at the hepatopancreatic ampulla from T2D subjects
were hyperplastic, showed a higher proliferation rate, and
contained more insulin positive cells. These in situ observa-
tions were paralleled by in vitro data. When hBTSCs were cul-
tured under high glucose concentrations, they committed
toward a pancreatic islet fate that included beta cells.
Taken together, our data indicate that high glucose concen-
trations are able to induce BTSC commitment toward pancre-
atic islet fates and that, in our models, BTSC activation induced
by hyperglycemia is firstly characterized by BTSC proliferation
and, subsequently, by the induction of beta cell differentiation.
In rodents, the presence of extrapancreatic insulin-
producing cells has already been described in multiple organs
and associated with experimental hyperglycemia [30]. In addi-
tion, cells exhibiting a glucose-stimulated insulin secretion
have been described within EHBT [31, 32]. Moreover, studies
in genetically manipulated animals have indicated that pan-
creatic differentiation could be induced in the biliary tract
[33–35]. Finally, Sox9-positive cells in the liver and biliary tract
can be reprogrammed to pancreatic cells by the overexpres-
sion of three transcription factors (Pdx1, Ngn3, and MafA),
determining an improvement of glycemic profiles [8]. In this
study, we show insulin-positive, duct-like structures ectopic to
the pancreas and within the BTSC niches within the biliary
tree represent a normal response to the administration of
STZ, and their appearance is associated with the spontaneous
upregulation of MafA.
CONCLUSIONS
Our data indicate that the PBG compartment is activated in
diabetes, and the cells within the PBGs are involved in rescu-
ing pancreatic islet loss. These data suggest that PBGs repre-
sent a target of genetic or pharmacological manipulations
triggering their expansion and differentiation towards insulin-
producing cells. In this light, our results open new approaches
in the management of diabetes based on the modulation of
the PBG niches.
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